Obsidian Therapeutics, Inc. (OBX)

PriceLoading quote

Financial charts

Revenue

No reported data

Net income

Free cash flow

Total cash / debt

CashTotal debt

Financial statements

2 annual periodsNewest to oldest
20252024
Research & development$0$3.8M
Operating income−$2.5M−$20.2M
Net income$149.0M−$19.0M
Diluted EPSper diluted share$0.64-$0.34

Insider buys & sells

Jul 1, 2024Jun 30, 2026
Buys0$0.00 disclosed value
Sells (SEC code S)0$0.00 disclosed value
0 recent transactions
No insider transactions transactions were reported in the stored SEC coverage.